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Objectives: Preeclampsia (PE) affects 2–5% of pregnant women. Hypertensive disorders of 
pregnancy are associated with adverse maternal and perinatal outcomes.  
Material and methods: This study included 88 women showing gestational hypertension 
(GH) or PE symptoms, and their newborns.  
Results: The rate of FGR was 43% for mothers with PE, compared to 8% with GH. The 
association was significant, p = < 0.001 but with moderate strength, Cramer’s V = 0.40. The 
risk of FGR increased nine times when PE occurred, as the odds ratio was 9.25 (CI: 2.46–
34.83), p = 0.001. PE was associated with FGR risk if delivery time was less than 34 weeks 
compared to a delivery time of more than 34 weeks. This was 82% of FGR cases for < 34 
weeks, compared with 35% of cases in > 34 group, (p = 0.001; Cramer’s V = 0.50). PE was 
also associated (p = 0.01, Cramer’s V = 0.27) with the type of delivery, as the caesarean 
section rate was 74%, compared to 50% in the GH group. This made it three times higher the 
likelihood of delivery by caesarean section, as the odds ratio was 3.10 (CI: 1.24–7.75), 
p=0,02. Delivery time was significantly (p < 0.001) shortened to 38 weeks (27–41), 
compared to 40 weeks (38–42) GH mothers. There was no distinction in median age for PE 
and GH mothers (p = 0.124). The overall clinical status of neonates was proportional despite 
the mother’s PE. The sum of Apgar points in the first, and then the second to third minute, 
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did not differ significantly, p = 0.370 and 0.560, respectively. The number of peripheral 
blood platelets and leucocytes was not reduced (p = 0.821 and 0.534) in infants when the 
mother suffered from PE.  
Conclusions: The prediction of adverse maternal outcomes from hypertensive diseases of 
pregnancy is key to optimal management, including the timing of delivery and planning for 
the most appropriate place of care.   
Key words: preeclampsia; gestational hypertension; complications; neonates; perinatal 
outcome; neonatal outcome 
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INTRODUCTION 
Preeclampsia (PE) affects 2–5% of pregnant women. It is one of the leading causes of 
maternal and perinatal morbidity and mortality, especially the early onset of PE [1, 2]. About 
76,000 women and 500,000 babies die each year because of PE [1, 3]. 
According to the ISSHP PE, transient gestational hypertension and gestational 
hypertension (GH) are characterized by the new onset of hypertension (blood pressure ≥ 140 
mmHg or ≥ 90 mmHg) at or after 20 weeks of gestation [4]. It is therefore important to have 
normal blood pressure readings documented either pre-pregnancy or in early pregnancy 
before there has been much pregnancy-related decrease in blood pressure [4–6].  
GH is hypertension arising de novo after 20 weeks of gestation in the absence of 
proteinuria and without biochemical or hematological abnormalities, usually not 
accompanied by FGR. Outcomes in pregnancies complicated solely by GH are generally 
good, however, about a quarter of women with GH (particularly those who present at < 34 
weeks) will progress to PE and have poorer outcomes [4].  
 
There are early-onset PE (before 34 weeks of gestation) and late-onset PE (≥ 34 
weeks gestation). Early-onset PE is less prevalent but has higher rates of maternal morbidity, 
perinatal death and severe neonatal morbidity compared to the late-onset disease [7]. In the 
late-onset PE women most often have minimal or no abnormal vascular remodeling of the 
spiral arteries and no intrauterine FGR appears [8].  
PE is also associated with adverse neonatal outcomes beyond morbidity caused by 
preterm birth. Although severe neonatal outcomes were less common at later gestational 
ages, there was an elevated neonatal risk due to PE even if it was possible to deliver all 
infants at term. Most common complications included increased perinatal mortality (OR 2.2) 
and an elevated risk for admission of the neonate to the intensive care unit [9].  
Neonatal mortality: It has been estimated that the hypertensive disorders of pregnancy 
precede 10% of early neonatal deaths (8/1000 live births) and late neonatal deaths (3/1000 
live births). About 1.5–2 million neonatal deaths a year [10, 11] because of iatrogenic 
prematurity, FGR and fetal overgrowth, hypertensive disorders of pregnancy are identifiable 
risk factors for newborn morbidity [12].  
In this study, we aimed to determine the risk of perinatal and neonatal complication in 
a woman with PE. Additionally, we have evaluated if the standard of care of hypertension in 
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pregnancy is sufficient to minimize deleterious effects in newborns. 
 
MATERIAL AND METHODS 
This single-center, prospective study aimed to assess perinatal and neonatal outcomes 
in pregnant women burdened with GH or PE. Patients were followed up throughout the 
pregnancy to collect data on clinical symptoms related to hypertension. Next, the perinatal 
and neonatal outcome was estimated to determine whether this condition affects a newborn’s 
healthiness. The study was supported with the Polish NCN no. 2014/15/B/NZ5/03499 
Pregnant women 
Patients qualified for the study were recruited among the patients of Department of 
Obstetrics Medical University of Gdansk, Poland. We have recruited a cohort of pregnant 
woman, hospitalized between April 2015 and July 2017. Based on clinical symptoms and 
laboratory markers, patients were classified as gestational hypertension group (n=44) and PE 
group (n=44) during the admission to the clinic due to exacerbation of the symptoms. The 
patients were hospitalized at various periods of pregnancy. The majority were admitted 
beyond 34th week of pregnancy. Those admitted prior to 32nd week of pregnancy were 
admitted due to exacerbation of hypertension, worsening of general condition of FGR. The 
median period of gestation differs (p < 0.001) between PE and GH, as it was 36 (min. 27; 
max 41) vs 39 (min 35; max 42) weeks, respectively. Patients qualified for the study followed 
routinely obstetrical control visits as advised by the Polish standards of medical care during 
pregnancy. The basic information of the study population is given in Table 1. 
 







Age (years, mean ± SD) 28 ± 4 30 ± 4.6 0.1 














Parity    
     0 36 34 NT 
     1 7 7 NT 
     >1 1 3 NT 
 
a2 test of association or Mann-Whitney U-test comparing PE vs GH; PE — preeclampsia; 
GH — gestational hypertension; NT — not tested 
 The study inclusion criteria were 27 to 42 weeks of gestation, singleton pregnancy with 
GH or PE but without co-morbidities.  
Infants     
Infants included in the study were all born in the Department of Obstetrics, Medical 
University of Gdańsk. They were singleton neonates born to mothers with either GH or PE, 
with no other comorbidities. 
Methods 
PE was diagnosed in patients with high blood pressure (24-h respiratory rate records) 
and i.e., new-onset proteinuria. The blood pressure was ≥ 140/90 mmHg on two occasions 
that are at least four hours apart and proteinuria. In the absence of proteinuria, PE was 
diagnosed in women with hypertension with thrombocytopenia, impaired liver function, a 
new development of renal insufficiency, pulmonary edema, new-onset cerebral or visual 
disturbances, or uteroplacental dysfunction, including FGR.  
FGR was diagnosed as fetal AC/EFW < 10th percentile with a PI in UA > 95th 
percentile or a PI in UA > 95th percentile, or AC/EFW < 3rd percentile, or the AEDF in the 
UA [13]. 
Neonatal wellbeing was recorded after birth (Apgar score). Parameters included in the 
analysis were neonatal body weight, week of gestation at birth and mode of delivery. The 
morphology was performed 24–48 hours after delivery.  
Statistics 
We used Statistica 11.0 (Statsoft). All comparisons were made with the nonparametric 
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Mann-Whitney U test. Significance was set at p < 0.05. Data were presented as medians with 
interquartile range and visualized with bar graphs. The tops of each bar indicate means, while 
lines represent 95% confidence intervals. The odds ratio (OR) was given as standard error 
and 95% confidence interval. Significance was set at p < 0.05. 
RESULTS 
The time of delivery varied between the two groups. In our study PE mothers had 
delivered significant statistically earlier (p < 0.001) compared to GH as the median delivery 
time was 38 (min 27; max 41) vs 40 (min 28; max 42) week of pregnancy. Similarly, 
significant statistically earlier hospital administration time was noted for PE compared to GH 
mothers (p < 0.001), as it was 36 (min 27; max 41) vs 39 (min 35; max 42) week of 
pregnancy (Fig. 1). There was no statistical difference (between the duration of symptoms 
from the exacerbation of the disease to the delivery in the PE and GE group (min 0; max 6 
weeks) U test 0.167 (Fig. 1). 
 
 
Figure 1. The clinical outcome of preeclampsia. A the rate of fetal growth restriction in PE 
and GH groups, significantly higher in PE; B significantly reduced child’s body weight when 
the mother suffered from PE compared to GH; C significantly higher rate of cesarean 
delivery by mothers suffering from PE compared to GH; * significant set to 0.05; 44 of 




In this study, the clinical consequences of PE have been assessed thoroughly. The 
most important observation was that PE increased the risk of FGR. This was noticeable as the 
rate of FGR was 43% (18/42) for mothers with PE, compared to 8% (3/40) with gestational 
hypertension. The association was significant, p < 0.001 but with moderate strength, 
Cramer’s V = 0.40. Thus, the risk of FGR increased nine times when PE occurred, as the 
odds ratio was 9.25 (CI: 2.46–34.83), p = 0,001 (Fig. 2A). 
PE was associated with FGR risk if delivery time was less than 34 weeks (11 mothers) 
compared to delivery time above 34 weeks (31 mothers). This was 82% (9/11) of FGR cases 
for < 34 weeks, compared with 35% (8/23) of cases in the > 34 group, (p = 0.001; Cramer’s 
V = 0.50). 
In the GH group most of the patients were treated in monotherapy mode with the use 
of methyldopa (Dopegyt). The dosages used varied form 500 mg per day to 2000 mg per day. 
The second drug in patients qualified for a two drugs therapy was a calcium channel blocker. 
 The drug most used was verapamil (Isoptin) (9 patients — 20.5%). In the PE group we 
observed that patients were additionally treated with labetalol (8 patients —18.1%) Among 
the patients using labetalol the dose was between a 100 mg and 200 mg per day. Within the 
PE group there was a small percentage of patients treated with urapidil (Ebrantil / Tachyben)- 
(6 patients — 13.6%). In the group of patients treated with urapidil the authors noted a 
concurrent use of magnesium sulphate as eclampsia was a common condition among patients 
in this group. 
The child’s body weight was also lower when the mother suffered from PE (p<0.001), 
as the median was 2630 g (min = 780; max = 4420) compared to 3500 g (min = 2060; max = 
4360) with gestational hypertension (Fig. 2B). Further, PE was associated (p = 0.010, 
Cramer’s V = 0.27) with the type of delivery, as the cesarean section rate was 74% (31/42), 
compared to 50% (20/40) in the gestational hypertension group (Fig. 2C). This made it three-
times higher the likelihood of delivery by caesarean section, as the odds ratio was 3.10 (CI: 
1.24–7.75), p = 0.020. Also, delivery time was significantly (p < 0.001) shortened to 38 
weeks (min = 27; max = 41), compared to 40 weeks (min = 38; max = 42) for gestational 
hypertension mothers. The rate of miscarriage was lower (p = 0.050; Cramer’s V = 0.21) for 
mothers with PE reaching 7% (3/39) when compared with the opposite 24% (10/42). There 
was no distinction in median age for PE and GH mothers (p = 0,124; Fig. 2D). 
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Figure 2. The clinical outcome of PE. A) the rate of fetal growth restriction in PE and GH 
groups, significant higher in PE; B) significant reduced child’s body weight when mother 
suffered from PE compared to GH; C) significant higher rate of caesarean delivery by 
mothers suffering from PE compared to GH; D) significant higher rate of miscarriage by 
mothers suffering from GH compared to PE; * significant set to 0.05; 44 of patients both in 
PE and GH groups. 
Of note is that the overall clinical status of neonates was proportioned despite the 
mother’s PE. The sum of Apgar points in the first, and then the second to third minute, did 
not differ significantly, p = 0.370 and 0.560 respectively. Up to 8 out of 42 of children born 
from mothers with PE had 4 to 7 Apgar points in the first minute and 34 had equal or higher 
than 8 points. In the second to  third minute, the number of neonates that recorded equal or 
higher than 8 Apgar points increased to 40, and only two had 4 to 7 points. In contrast, in the 
first minute 5 out of 42 of neonates, and then only one in the second to third minute, had 4 to 
7 Apgar points when born from gestational hypertension mothers (Fig. 3A, 3B). The number 
of peripheral blood platelets and leucocytes wasn’t reduced (p = 0.821 and p = 0.534) in 
infants when the mother suffered from PE, as it was 247000/µL (min = 29000/µL; max = 
585000/µL) for platelets and 6.89 ×103/µL (min=12.27 × 103/µL; max = 21.80 × 103/µL) 
leucocytes, compared to 252000/µL (min = 58000/µL; max = 359000/µL) for platelets and 
7,04 × 103/µL (min = 12.90 × 103/µL; max = 21.21 × 103/µL) leucocytes in GH group. 
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Both BMI and bodyweight of mothers with PE was reduced significantly, p = 0.01 
and p = 0.010 when compared to the gestational hypertension group. The median value was 
33 (min = 26; max = 42) for the gestational hypertension group and 30 (min = 21; max = 46) 
for the former (Fig. 3C). Similarly, the body weight was 83 kg (min = 56; max = 132) for 
mothers with PE and 92 kg (min = 65; max = 125) for the latter (Fig. 3D).  
 
Figure 3. The clinical outcome of preeclampsia. A) no significantly different number of 
Apgar points (4 to 7) in first minute in PE and GH groups; B) no significantly different 
number of Apgar points (4 to 7) in second to third minutes in PE and GH groups; C) 
significant lower BMI values of mothers suffering from PE compared to GH; D) significant 
lower body weight values of mothers suffering from PE compared to GH; * significant set to 
0,05; 44 of patients both in PE and GH groups. 
 
DISCUSSION 
Obstetricians managing women with preterm PE are faced with the challenge of 
balancing the need to achieve fetal maturation in utero with the risks to the mother and fetus 
of continuing the pregnancy longer. These risks include progression to eclampsia, 
development of placental abruption and HELLP syndrome.  
In this study, despite a nine-times increased risk of FGR when PE occurred, the 
overall clinical status of neonates was comparable to the gestational hypertension group. 
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Although PE may cause a low Apgar score, the need for NICU admission was not evident for 
our cohort [17]. The sum of Apgar points did not differ significantly. The only short-term 
complications were reduced child’s body weight. 
Another important observation was PE linked with the delivery by caesarean section. 
In our study, the risk of caesarean section was even three times higher as compared to the GH 
group. This was in line with previous reports that 25% of PE patients require delivery before 
37 weeks About one-third of preterm births are medically indicated, PE is the primary 
indication for iatrogenic preterm delivery [23, 24]. 
Maternal PE may affect other hematological parameters in the newborn. It may 
provoke neonatal thrombocytopenia (defined as a platelet count less than 150000/uL), 
occurring in the first three days of life, with most cases resolving by the tenth day [26].  
Another hematological complication found in neonates is neutropenia (defined as neutrophil 
count < 500). It has a variable course, lasting up to several weeks. A potential mechanism of 
PE mediated neutropenia is that uteroplacental insufficiency inhibits fetal bone marrow 
production of the myeloid line [26]. We did not confirm these observations as neither platelet 
nor leucocyte counts were affected in children born from PE mothers as compared to GH 
mothers. 
Looking at mothers that developed PE, we have found that age was indistinct from the 
GH group, but what was interesting was that the BMI was lower for PE women. This is only 
partially in line with previous reports. Advanced maternal age ≥ 35 years old at the time of 
delivery is associated with 1.2 to 3-fold increased risk of developing PE [14–16].  Predictive 
probability of PE increases in pregnant women ≥ 35 years old. The probability further 
increases rapidly in pregnant women ≥ 40 years old. But the maternal age is not associated 
with increased risk of early-onset PE [17]. The increased risk of developing PE has been 
widely reported in nulliparous women. Duckitt K. et al. [18], showed the increased risk of PE 
3-fold in nulliparous patients. Previous reports reported that BMI ≥ 30 kg/m2 has a 2 to 4-fold 
higher risk for PE [19–21].  
Several fetal complications are associated with PE, especially when the disease is 
severe or in early onset: FGR, oligohydramnios, IUFD, preterm delivery, non-reassuring 
FHR during delivery, low Apgar scores [22].  
This paper shows that precise follow up of pregnant women developing hypertension 
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during pregnancy may diminish the overall risk associated with this serious clinical 
condition. Despite the higher likelihood of FGR and other short-term complications like the 
risk of caesarian delivery and premature time of delivery, the overall clinical status of 
children born from mothers suffering from PE was normal. This is probably due to early 
diagnosis of hypertension and punctilious follow up of pregnant women. 
In conclusion, the only definitive treatment of PE is to deliver the placenta and thus 
the neonate. Because of the two conflicting interests of pregnant woman and fetus, the time 
of delivery is one of the main challenges of PE, especially in pregnant women with early-
onset PE. Therefore, careful diagnosis and the proper assessment of the risk factors remains 
crucial in the management of the hypertensive diseases of pregnancy including the halting of 
the pregnancy. 
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